Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 2/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 8/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151619 | 0.91 | MAPT (0.57) | ITGB1ITGA4KDM4EPOLBMAPT | |
| SCHEMBL5151715 | 0.90 | MEN1 (0.54) | ITGB1ITGA4KDM4EPOLBMAPT | |
| SCHEMBL6166911 | 0.88 | MAPT (0.58) | ITGB1ITGA4KDM4EPOLBMAPT | |
| SCHEMBL4683165 | 0.87 | ITGA4 (0.67) | ITGB1ITGA4POLBMAPTMEN1 | |
| SCHEMBL6597529 | 0.87 | MEN1 (0.56) | ITGB1ITGA4KDM4EPOLBMAPT | |
| SCHEMBL5155303 | 0.86 | ITGA4 (0.55) | ITGB1ITGA4POLBMEN1KMT2A | |
| SCHEMBL5150328 | 0.86 | ITGB1 (0.52) | ITGB1ITGA4MAPTMEN1KMT2A | |
| SCHEMBL5152156 | 0.86 | KMT2A (0.56) | ITGB1ITGA4KDM4EMAPTMEN1 | |
| SCHEMBL5152186 | 0.86 | ALDH1A1 (0.56) | ITGB1ITGA4POLBMAPTMEN1 | |
| SCHEMBL8868308 | 0.86 | MAPT (0.55) | ITGB1ITGA4KDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0842196-B1 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-7001921-B1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-6875743-B1 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1189612-A4 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI SEIYAKU CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248713-B1 | OLIGOPEPTIDE FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BIOGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6239108-B1 | Cell adhesion inhibitors | BIOGEN, INC. | 2001-05-29 | — | — | US | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| EP-0842196-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997003094-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-01-30 | — | — | WO | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | ITGB1 11/4885ITGA4 37/4885KDM4E 3595/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ITGB1 8/4885ITGA4 4/4885KDM4E 409/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | ITGB1 7/4885ITGA4 5/4885KDM4E 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.